FIELD: biochemistry.
SUBSTANCE: invention relates to a rodent expressing humanized polypeptide 1 of programmed cell death (PD-1), to its cell, tissue, as well as to a method for its production. Also disclosed is a method for assessing the pharmacokinetic properties of a drug specifically affecting human PD-1, comprising using said rodent.
EFFECT: invention enables to efficiently obtain a rodent expressing humanized polypeptide 1 of programmed cell death.
26 cl, 8 dwg, 8 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANIMALS OTHER THAN HUMANS HAVING A HUMANISED CLUSTER GENE OF DIFFERENTIATION 47 | 2015 |
|
RU2728412C2 |
| GENETICALLY MODIFIED ANIMALS OTHER THAN HUMANS FOR PRODUCING THERAPEUTIC ANTIBODIES AGAINST PEPTIDE-MHC COMPLEXES, METHODS FOR PRODUCTION AND VERSIONS OF USE THEREOF | 2019 |
|
RU2819525C2 |
| ANIMALS OTHER THAN A HUMAN HAVING A STRUCTURED ANGPTL8 GENE | 2017 |
|
RU2742354C2 |
| HUMANIZED T-CELL MEDIATED IMMUNE RESPONSES IN NON-HUMAN ANIMALS | 2016 |
|
RU2732628C2 |
| NON-HUMAN ANIMALS HAVING HUMANIZED LYMPHOCYTE-ACTIVATION GENE 3 | 2016 |
|
RU2745403C2 |
| NON-HUMAN ANIMALS EXPRESSING HUMANISED COMPLEX CD3 | 2015 |
|
RU2726446C2 |
| DITRA MODELS IN NON-HUMAN ANIMALS AND THEIR USE | 2019 |
|
RU2804448C2 |
| NON-HUMAN ANIMALS HAVING HUMANIZED GENE OF DIFFERENTIATION CLUSTER 274 | 2015 |
|
RU2711729C2 |
| GENETICALLY MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO | 2015 |
|
RU2799086C2 |
| ANIMALS OTHER THAN HUMANS CHARACTERIZED IN EXPANSION OF HEXANUCLEOTIDE REPEATS AT LOCUS C9orf72 | 2017 |
|
RU2760877C2 |
